Genomic and immunotherapy tumor testing to improve survival in stage IV non-small cell lung cancer

You may qualify if

• AIM 1-3
• Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group [ECOG] performance status, and any NSCLC - adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;; Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)
• English speaking; and
• Willing to provide access to medical records, insurance and billing data, biospecimens and respond to questionnaires, typically by phone, but possibly to include online or in-person surveys
• AIM 3 ONLY
• Patients must be current smokers who smoke at least one cigarette most days per week, or recent quitters who smoked at least one cigarette most days per week (< 3 months); and
• Household members must be current smokers, defined as smoking at least one cigarette most days per week
• Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection

You can't join if

• Being treated with definitive chemoradiotherapy or surgery
• Receiving treatment for advanced lung cancer for over one month before enrollment; OR